SOURCES SOUGHT
65 -- Adenovirus Vaccine
- Notice Date
- 3/10/2011
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- SPM2DP11R0102
- Archive Date
- 4/29/2011
- Point of Contact
- Neil Mcavinue, Phone: 215-737-3126
- E-Mail Address
-
Neil.Mcavinue@dla.mil
(Neil.Mcavinue@dla.mil)
- Small Business Set-Aside
- N/A
- Description
- The Defense Logistics Agency - Troop Support is seeking sources capable of providing Adenovirus Vaccine, NSN 6505-01-578-0003. The vaccine shall be enteric-coated tablets of live, adenovirus type 4 and type 7 suitable for oral administration only. One dose shall constitute one tablet each of adenovirus type 4 and adenovirus type 7 vaccine. DLA Troop Support has annual requirements estimated at 270,000 doses (540,000 tablets). The quantities indicated are annual estimates only. The actual requirement per year might be more. Ordered quantities shall be delivered to military recruiting activities located throughout the United States. Delivery is scheduled on a monthly basis to these activities. The Government will guarantee a minimum purchase of 205,000 doses per year. This is a request for information and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. All submitted information shall remain with the U.S. Government and will not be returned. The Government is currently soliciting proposals for adenovirus vaccine under separate solicitation SPM2DP11R0002. ***CURRENTLY MARKETED VACCINE*** If your firm currently markets adenovirus vaccine, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture vaccines described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this RFI will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for adenovirus vaccine. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically in pdf format and emailed to neil.mcavinue@dla.mil
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/SPM2DP11R0102/listing.html)
- Record
- SN02398429-W 20110312/110310234947-a5b4220f995dc69dc248e9ef7da68493 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |